News

Tuesday, 7. June 2022 | Filed under Company News

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

– New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint

– Company establishes U.S. subsidiary to accelerate international operations

ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq. Read more…

Wednesday, 25. May 2022 | Filed under Company News

Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer

– Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities

– Company recently initiated clinical trial of novel digital therapeutic for childhood myopia

Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the Company.

Mark Wuttke brings more than two decades of healthcare business expertise, in particular, comprehensive experience in the development and commercialization of ophthalmology products at Novartis, a global leader in eye health. He also has a strong track record in corporate strategy and branding. Read more…

Wednesday, 25. May 2022 | Filed under Company News

Neonatal Diagnostics Company InfanDx AG Completes Two-Year Patient Follow-Up in BANON Study

— Clinical data curation and evaluation ongoing

— Follow-up rate of 77% fully meets expectations (70-80%)

— Final HIE biomarker panel validation data expected by end of Q3-2022

 

InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, announced at an investigator meeting during the recent 48th Annual Meeting of the German Society for Neonatology and Pediatric Intensive Medicine that the clinical 2-year follow-up of patients originally enrolled in the BANON study was formally completed. The study is designed to validate novel diagnostic biomarkers of Hypoxic-Ischemic Encephalopathy (HIE).

Read more…